BTK-IN-18 (compound 41; 10, 25, 45 mg/kg; IP; single dose) causes robust dose-dependent inhibition of both CD69 and CD86[1].
BTK-IN-18 (iv; 1 mg/kg) has a T1/2 of 5.3 hours, a CL of 19 mL/min/kg, and a Vss of 1.3 L/kg for rats[1].
| Animal Model: | Mice[1] |
| Dosage: | 10, 25, 45 mg/kg |
| Administration: | IP; single dose |
| Result: | Caused robust dose-dependent inhibition of both CD69 and CD86 (74.8 %, 50.3 %, and 21.5 % respectively).
|
| Animal Model: | |
| Dosage: | |
| Administration: | |
| Result: | Pharmacokinetic Parameters of BTK-IN-18 in rats[1].
| IV (1 mg/kg) | PO (5 mg/kg) | | Tmax (h) | | 1.6 | | Cmax (h?mg/mL) | 321 | | | AUCinfi (h?mg/mL) | 1013 | 1421 | | t1/2 (ng/mL) | 5.3 | | | CL (mL/min/kg) | 19 | | | Vss (L/kg) | 1.3 | | | F (%) | 23% | |
|